Preclinical and clinical studies in well-defined cohorts are needed to exploit IL-37’s and SIGIRR’s potential to serve as novel molecular markers that could facilitate more personalized and precise approaches and ameliorate the prognosis and risk stratification of BLCA patients. This evidence concerns the gene IL37 and bladder transitional cell carcinoma.